Lenalidomide is an immunomodulatory drug and a structural analog of thalidomide. It has several pharmacological effects, including modulation of immune-cell activity, inhibition of selected inflammatory signaling pathways, inhibition of angiogenesis, and suppression of abnormal cell survival.
It may be used:
Lenalidomide continues to be extensively studied. The U.S. National Cancer Institute lists numerous clinical trials involving lenalidomide, including studies in multiple myeloma and lymphoma and trials evaluating combinations with newer anticancer medicines.
Maintenance treatment with lenalidomide following autologous transplantation in multiple myeloma has been extensively evaluated. In one randomized study, median overall survival was 113.8 months with lenalidomide versus 84.1 months with placebo; five-year overall survival was 76% versus 64%.
Lenalidomide is also associated with clinically important risks, including myelosuppression and thromboembolic events. Treatment therefore requires appropriate monitoring of blood counts, kidney function, and other parameters as directed by the treating physician.
Lenalidomide is used for certain hematologic cancers and related disorders, including:
The medicine affects immune mechanisms and abnormal cells and may also inhibit the formation of new blood vessels needed for tumor growth.
Capsules should be taken orally exactly as prescribed by the treating physician. The dose and duration depend on the diagnosis, treatment regimen, kidney function, blood counts, and individual tolerability. The capsule should be swallowed whole and should not be opened, crushed, or chewed. Do not change the dose or discontinue treatment without medical advice.
